Picard Medical is trading at $11.00 (+12.24%) in pre-market, with no clearly identified new company-specific announcement for August 27, 2026.
- Second-quarter revenue was approximately $2.95 million versus roughly $1.55 million expected; the report was released August 19.
- A shareholder investigation announced August 25 alleges fiduciary-duty breaches, social-media promotion, nominee accounts, and omitted risk disclosures.
- The gain appears speculative and highly volatile, with no confirmed catalyst explaining the move.